Lack of involvement of the GNAS1 T393C polymorphism in prostate cancer risk in a Japanese population

Anticancer Research

Volumn 28, Issue 6 A, 2008, Pages 3711-3716

  Watanabe, Masatoshi ^a,b   Hirokawa, Yoshifumi ^a   Tsuji, Mayumi ^c   Yanagawa, Makoto ^d   Murata, Tetsuya ^e   Suzuki, Hiroyoshi ^f   Ichikawa, Tomohiko ^f   Katoh, Takahiko ^c   Sugimura, Yoshiki ^a   Shiraishi, Taizo ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA NATIONAL UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d SAISEIKAI MATSUSAKA GENERAL HOSPITAL   (Japan)

^e SUZUKA GENERAL HOSPITAL   (Japan)

^f CHIBA UNIVERSITY   (Japan)

Author keywords

GNAS1; Polymorphism; Prostate cancer

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN GSA; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GNAS1 GENE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; T393C GENE;

ADENOCARCINOMA; AGED; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 58149156691     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ and Timms B: Human prostate cancer risk factors. Cancer 101(10 Suppl): 2371-2490, 2004.
3. Stacewicz-Sapuntzakis M, Borthakur G, Burns JL and Bowen PE: Correlations of dietary patterns with prostate health. Mol Nutr Food Res 52: 114-130, 2008.
4. Watanabe M, Nakayama T, Shiraishi T, Stemmermann GN and Yatani R: Comparative studies of prostate cancer in Japan versus the United States. A review. Urol Oncol 5: 274-283, 2000.
5. Tabata N, Ohno Y, Matsui R, Sugiyama H, Ito Y, Tsukuma H and Oshima A: Partial cancer prevalence in Japan up to 2020: estimates based on incidence and survival data from population-based cancer registries. Jpn J Clin Oncol 38: 146-157, 2008.
6. Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R and Shiraishi T: Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5 alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 92: 683-686, 2001.
7. Platz EA and Giovannucci E: The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92: 237-253, 2004.
8. Katoh T, Yamano Y, Tsuji M and Watanabe M: Genetic polymorphisms of human cytosol glutathione S-transferases and prostate cancer. Pharmacogenomics 9: 93-104, 2008.
9. Weinstein LS, Yu S, Warner DR and Liu J: Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 22: 675-705, 2001.
10. Weinstein LS, Chen M, Xie T and Liu J: Genetic diseases associated with heterotrimeric G proteins. Trends Pharmacol Sci 27: 260-266, 2006.
11. Koelle MR: Heterotrimeric G protein signaling: getting inside the cell. Cell 126: 25-27, 2006.
12. Chanson P, Salenave S and Orcel P: McCune-Albright syndrome in adulthood. Pediatr Endocrinol Rev 4(Suppl 4): 453-462, 2007.
13. Lania A, Mantovani G and Spada A: Genetics of pituitary tumors: focus on G-protein mutations. Exp Biol Med (Maywood) 228: 1004-1017, 2003.
14. Tanabeu Y, Nakahara S, Mitsuyama S, Ono M and Toyoshima S: Breast cancer in a patient with McCune-Albright syndrome. Breast Cancer 5: 175-178, 1998.
15. Huston TL and Simmons RM: Ductal carcinoma in situ in a 27-year-old woman with McCune-Albright syndrome. Breast J 10: 440-442, 2004.
16. Congedo V and Celi FS: Thyroid disease in patients with McCune-Albright syndrome. Pediatr Endocrinol Rev 4(Suppl 4): 429-433, 2007.
17. Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D, Lloyd DD and Brown MJ: Association of the G(s) alpha gene with essential hypertension and response to beta-blockade. Hypertension 34: 8-14, 1999.
18. Abe M, Nakura J, Yamamoto M, Jin JJ, Wu Z, Tabara Y, Yamamoto Y, Igase M, Kohara K and Miki T: Association of GNAS1 gene variant with hypertension depending on smoking status. Hypertension 40: 261-265, 2002.
19. Chen Y, Nakura J, Jin JJ, Wu Z, Yamamoto M, Abe M, Tabara Y, Yamamoto Y, Igase M, Bo X, Kohara K and Miki T: Association of the GNAS1 gene variant with hypertension is dependent on alcohol consumption. Hypertens Res 26: 439-444, 2003.
20. Yamamoto M, Abe M, Jin JJ, Wu Z, Tabara Y, Mogi M, Kohara K, Miki T and Nakura J: Association of a GNAS1 gene variant with hypertension and diabetes mellitus. Hypertens Res 27: 919-924, 2004.
21. Frey UH, Eisenhardt A, Lümmen G, Rübben H, Jöckel KH, Schmid KW and Siffert W: The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 14: 871-877, 2005.
22. Frey UH, Alakus H, Wohlschlaeger J, Schmitz KJ, Winde G, van Calker HG, Jöckel KH, Siffert W and Schmid KW: GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 11: 5071-5077, 2005.
23. Frey UH, Lümmen G, Jäger T, Jöckel KH, Schmid KW, Rübben H, Müller N, Siffert W and Eisenhardt A: The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 12: 759-763, 2006.
24. Frey UH, Nückel H, Sellmann L, Siemer D, Küppers R, Dürig J, Dührsen U and Siffert W: The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. Clin Cancer Res 12: 5686-5689, 2006.
25. Hahn S, Frey UH, Siffert W, Tan S, Mann K and Janssen OE: The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome. Eur J Endocrinol 155: 763-770, 2006.
26. Schmitz KJ, Lang H, Frey UH, Sotiropoulos GC, Wohlschlaeger J, Reis H, Takeda A, Siffert W, Schmid KW and Baba HA: GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia 9: 159-165, 2007.
27. Minoretti P, Politi P, Coen E, Di Vito C, Bertona M, Bianchi M and Emanuele E: The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample. Neurosci Lett 397: 159-163, 2006.
28. Otterbach F, Callies R, Frey UH, Schmitz KJ, Wreczycki C, Kimmig R, Siffert W and Schmid KW: The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma. Breast Cancer Res Treat 105: 311-317, 2007.
29. Lehnerdt GF, Franz P, Zaqoul A, Schmitz KJ, Grehl S, Lang S, Schmid KW, Siffert W, Jahnke K and Frey UH: Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene. Clin Cancer Res 4: 1753-1758, 2008.
30. Kaderi MA, Murray F, Jansson M, Merup M, Karlsson K, Roos G, Aleskog A and Tobin G: The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia. Leuk Res 32: 984-987, 2008.
31. Shah GV, Rayford W, Noble MJ, Austenfeld M, Weigel J, Vamos S and Mebust WK: Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3′,5′-monophosphates and cytoplasmic Ca2+ transients. Endocrinology 134: 596-602, 1994.
32. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ and Fitzpatrick LA: Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and Chemotaxis. Prostate 30: 183-187, 1997.
33. Régnauld K, Nguyen QD, Vakaet L, Bruyneel E, Launay JM, Endo T, Mareel M, Gespach C and Emami S: G-protein alpha(olf) subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells. Oncogene 21: 4020-4031, 2002.
34. Chien J, Wong E, Nikes E, Noble MJ, Pantazis CG and Shah GV: Constitutive activation of stimulatory guanine nucleotide binding protein (G(S)alphaQL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene 18: 3376-3382, 1999.
35. Chien J and Shah GV: Role of stimulatory guanine nucleotide binding protein (GSalpha) in proliferation of PC-3M prostate cancer cells. Int J Cancer 91: 46-54, 2001.
36. Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P, Casey PJ and Daaka Y: Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem 280: 11583-11589, 2005.
37. Bagchi G, Wu J, French J, Kim J, Moniri NH and Daaka Y: Androgens transduce the G alpha S-mediated activation of protein kinase A in prostate cells. Cancer Res 68: 3225-3231, 2008.
38. Kelly P, Casey PJ and Meigs TE: Biologic functions of the G12 subfamily of heterotrimeric G proteins: growth, migration, and metastasis. Biochemistry 46: 6677-6687, 2007.
39. Kelly P, Moeller BJ, Juneja J, Booden MA, Der CJ, Daaka Y, Dewhirst MW, Fields TA and Casey PJ: The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc Natl Acad Sci USA 103: 8173-8178, 2006.
40. Kelly P, Stemmle LN, Medden JF, Fields TA, Daaka Y and Casey PJ: A role of the G12 family of heterotrimeric G proteins in prostate cancer invasion. J Biol Chem 281: 26483-26490, 2006.
41. Bian D, Mahanivong C, Yu J, Frisch SM, Pan ZK, Ye RD and Huang S: The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration. Oncogene 25: 2234-2244, 2006.